Andere Sprachen MediciNova, Inc.

Aktien

A0LF3U

US58468P2065

MNOV

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 01.05.2024			% 5 Tage	% 1. Jan.
1,29 ^USD	0,00 %		-4,80 %	-14,00 %

27.03.	MediciNova, Inc. erhält einen Zulassungsbescheid für ein neues Patent für MN-166 (Ibudilast) zur Behandlung von Makulaverletzungen in Japan	CI
12.03.	Medicinova gibt neue Daten und Ergebnisse von Mn-166 (Ibudilast) bei durch Chlorgas verursachten akuten Lungenverletzungen bekannt, die auf der 63. Jahrestagung der Society of Toxicology vorgestellt wurden	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting	03.04.
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)	03.04.
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	27.03.
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan	27.03.
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	27.03.
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society	21.03.
MediciNova : Corporate Presentation – March 15, 2024	15.03.
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology	12.03.
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	12.03.
MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers – February 29, 2024	29.02.
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15.02.
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	18.01.
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China	17.01.
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	17.01.
Top Premarket Gainers	12.01.
MediciNova Announces Abstract Regarding MN-166 in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22.12.
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22.12.
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22.12.
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22.12.
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	07.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MediciNova, Inc.

Aktien

A0LF3U

US58468P2065

MNOV

Andere Sprachen

Filter